The combination of TOP2A and HDAC inhibitors has been assessed in clinical trials for soft‐tissue sarcoma and T‐cell lymphoma, but not in osteosarcoma (NCT00878800, NCT01902225), and showed good efficacy and tolerance.65, 66. Here, HDAC9 is linked to soft tissue sarcoma.